We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
RVTY Launches New Kit in Europe for Newborn Type 1 Diabetes Detection
Read MoreHide Full Article
Key Takeaways
Revvity launches the GSP T1D 3plex kit for automated early screening of children at risk of T1D.
The assay uses dried blood spots and the GSP platform to support scalable, high-throughput screening.
RVTY gained 6% after the news; the kit will launch first in Europe and CE IVD-accepting markets.
Revvity, Inc. (RVTY - Free Report) recently launched the GSP T1D 3plex kit, a fully automated, CE-IVDR-certified multiplex autoantibody detection solution in Europe. The kit is designed to support population-wide screening for children at risk of developing type 1 diabetes (T1D) before symptoms appear. The solution uses capillary dried blood spot (DBS) samples and is processed on Revvity’s GSP instrument, extending the company’s screening capabilities from newborn screening into early childhood.
The GSP T1D 3plex kit will initially be available in Europe and other markets accepting CE IVD-marked products. However, the kit is yet to receive FDA clearance.
The GSP T1D 3plex kit aims to support emerging national T1D screening initiatives with a reliable and regulatory-compliant testing solution. It further strengthens Revvity’s growing diabetes portfolio, which covers research, clinical testing and service-based offerings.
Per management, the launch represents an important step in expanding the company’s child health screening capabilities by leveraging its expertise in newborn screening to enable earlier detection of T1D.
RVTY Stock Trend Following the News
Following the announcement, RVTY stock gained 6% at yesterday’s close. Year to date, shares of the company have rallied 55.7% compared with the industry’s 3.8% growth and the S&P 500’s 12% gain.
The launch expands Revvity’s diagnostic portfolio into population-scale early T1D screening and could create additional opportunities in the growing diabetes diagnostics market. The combination of automated testing, DBS-based sample collection and Revvity’s established GSP platform may support adoption among screening programs seeking scalable solutions for earlier identification of children at risk of T1D.
RVTY currently has a market capitalization of $15.86 billion.
Image Source: Zacks Investment Research
More on the GSP T1D 3plex Kit
The GSP T1D 3plex kit is designed to simultaneously detect autoantibodies associated with T1D, enabling identification of individuals who may be at risk before clinical symptoms emerge. Early screening can help identify individuals during earlier stages of disease, when intervention and monitoring may address complications associated with later diagnosis. Revvity’s T1D screening portfolio focuses on autoantibodies, including GAD, IA-2 and ZnT8.
The assay uses capillary DBS samples, providing a simple collection method suitable for scalable screening programs. Revvity’s GSP platform is a high-throughput, fully automated system that handles sample processing, measurement and results reporting, with DBS-based workflows designed to reduce manual steps and improve operational efficiency.
The company will present its T1D on-site installation and off-site testing solutions developed with Sanofi at the European Association for the Study of Diabetes meeting in Milan.
Industry Prospects Favoring the Market
Going by the data provided by Grand View Research, the global autoimmune disease diagnostics market is estimated to reach $6.4 billion in 2026 and is projected to witness a CAGR of 5.8% through 2033.
Factors such as the rising prevalence of autoimmune disorders, including type 1 diabetes, increasing demand for rapid and accurate diagnostic testing, growing adoption of disease-specific autoantibody assays and rising investments in autoimmune disease research are supporting market growth.
Other News
Revvity recently entered into a definitive agreement to acquire Human Cell Design (HCD), a France-based biotechnology company focused on human cell models and preclinical research solutions for metabolic diseases. The acquisition will bring HCD’s human pancreatic beta cell models into Revvity’s Life Sciences portfolio.
Last month, Revvity launched the SuperFlex prenatal screening system, a CE-IVDR-certified automated immunoassay instrument designed to expand access to prenatal and preeclampsia testing. Built for small to mid-sized laboratories and clinics, the platform brings reliable, rapid in-house screening capabilities to lower-volume testing environments. SuperFlex will initially be available in markets accepting CE-marked instruments, with expansion into Asia-Pacific planned for late 2026.
Veracyte, currently sporting a Zacks Rank #1 (Strong Buy), reported a second-quarter 2026 adjusted earnings per share (EPS) of 54 cents, which surpassed the Zacks Consensus Estimate by 25.6%. Revenues of $150.3 million beat the Zacks Consensus Estimate by 4.1%. You can see the complete list of today’s Zacks #1 Rank stocks here.
VCYT has an estimated earnings growth rate of 8.4% for 2026. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 41.8%.
Globus Medical, currently flaunting a Zacks Rank #1, reported a second-quarter 2026 adjusted EPS of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%.
GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.
Intuitive Surgical, carrying a Zacks Rank #2 at present, reported second-quarter 2026 adjusted EPS of $2.80, which beat the Zacks Consensus Estimate by 12.9%. Revenues of $2.89 billion surpassed the Zacks Consensus Estimate by 3.1%.
Intuitive Surgical has a long-term estimated growth rate of 14.9%. ISRG’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.5%.
View the Zacks #1 Rank List
Image: Shutterstock
RVTY Launches New Kit in Europe for Newborn Type 1 Diabetes Detection
Key Takeaways
Revvity, Inc. (RVTY - Free Report) recently launched the GSP T1D 3plex kit, a fully automated, CE-IVDR-certified multiplex autoantibody detection solution in Europe. The kit is designed to support population-wide screening for children at risk of developing type 1 diabetes (T1D) before symptoms appear. The solution uses capillary dried blood spot (DBS) samples and is processed on Revvity’s GSP instrument, extending the company’s screening capabilities from newborn screening into early childhood.
The GSP T1D 3plex kit will initially be available in Europe and other markets accepting CE IVD-marked products. However, the kit is yet to receive FDA clearance.
The GSP T1D 3plex kit aims to support emerging national T1D screening initiatives with a reliable and regulatory-compliant testing solution. It further strengthens Revvity’s growing diabetes portfolio, which covers research, clinical testing and service-based offerings.
Per management, the launch represents an important step in expanding the company’s child health screening capabilities by leveraging its expertise in newborn screening to enable earlier detection of T1D.
RVTY Stock Trend Following the News
Following the announcement, RVTY stock gained 6% at yesterday’s close. Year to date, shares of the company have rallied 55.7% compared with the industry’s 3.8% growth and the S&P 500’s 12% gain.
The launch expands Revvity’s diagnostic portfolio into population-scale early T1D screening and could create additional opportunities in the growing diabetes diagnostics market. The combination of automated testing, DBS-based sample collection and Revvity’s established GSP platform may support adoption among screening programs seeking scalable solutions for earlier identification of children at risk of T1D.
RVTY currently has a market capitalization of $15.86 billion.
Image Source: Zacks Investment Research
More on the GSP T1D 3plex Kit
The GSP T1D 3plex kit is designed to simultaneously detect autoantibodies associated with T1D, enabling identification of individuals who may be at risk before clinical symptoms emerge. Early screening can help identify individuals during earlier stages of disease, when intervention and monitoring may address complications associated with later diagnosis. Revvity’s T1D screening portfolio focuses on autoantibodies, including GAD, IA-2 and ZnT8.
The assay uses capillary DBS samples, providing a simple collection method suitable for scalable screening programs. Revvity’s GSP platform is a high-throughput, fully automated system that handles sample processing, measurement and results reporting, with DBS-based workflows designed to reduce manual steps and improve operational efficiency.
The company will present its T1D on-site installation and off-site testing solutions developed with Sanofi at the European Association for the Study of Diabetes meeting in Milan.
Industry Prospects Favoring the Market
Going by the data provided by Grand View Research, the global autoimmune disease diagnostics market is estimated to reach $6.4 billion in 2026 and is projected to witness a CAGR of 5.8% through 2033.
Factors such as the rising prevalence of autoimmune disorders, including type 1 diabetes, increasing demand for rapid and accurate diagnostic testing, growing adoption of disease-specific autoantibody assays and rising investments in autoimmune disease research are supporting market growth.
Other News
Revvity recently entered into a definitive agreement to acquire Human Cell Design (HCD), a France-based biotechnology company focused on human cell models and preclinical research solutions for metabolic diseases. The acquisition will bring HCD’s human pancreatic beta cell models into Revvity’s Life Sciences portfolio.
Last month, Revvity launched the SuperFlex prenatal screening system, a CE-IVDR-certified automated immunoassay instrument designed to expand access to prenatal and preeclampsia testing. Built for small to mid-sized laboratories and clinics, the platform brings reliable, rapid in-house screening capabilities to lower-volume testing environments. SuperFlex will initially be available in markets accepting CE-marked instruments, with expansion into Asia-Pacific planned for late 2026.
Revvity Inc. Price
Revvity Inc. price | Revvity Inc. Quote
RVTY’s Zacks Rank & Other Key Picks
Currently, RVTY carries a Zacks Rank #2 (Buy).
Some other top-ranked stocks from the broader medical space are Veracyte (VCYT - Free Report) , Globus Medical (GMED - Free Report) and Intuitive Surgical (ISRG - Free Report) .
Veracyte, currently sporting a Zacks Rank #1 (Strong Buy), reported a second-quarter 2026 adjusted earnings per share (EPS) of 54 cents, which surpassed the Zacks Consensus Estimate by 25.6%. Revenues of $150.3 million beat the Zacks Consensus Estimate by 4.1%. You can see the complete list of today’s Zacks #1 Rank stocks here.
VCYT has an estimated earnings growth rate of 8.4% for 2026. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 41.8%.
Globus Medical, currently flaunting a Zacks Rank #1, reported a second-quarter 2026 adjusted EPS of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%.
GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.
Intuitive Surgical, carrying a Zacks Rank #2 at present, reported second-quarter 2026 adjusted EPS of $2.80, which beat the Zacks Consensus Estimate by 12.9%. Revenues of $2.89 billion surpassed the Zacks Consensus Estimate by 3.1%.
Intuitive Surgical has a long-term estimated growth rate of 14.9%. ISRG’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.5%.